Sight Sciences(US:SGHT)2026-03-04 22:32Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, up from $0.3 million [17][19] - Gross margin was 87%, consistent with the prior year, with interventional glaucoma gross margin at 88% and interventional dry eye gross margin improved to 68% from 51% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] Business Line Data and Key Metrics Changes - Interventional dry eye revenue in Q4 was driven by the sale of approximately 700 Smart Lids to about 80 accounts, with 30 being new engagements [9][10] - Interventional glaucoma revenue growth was supported by a 2% increase in ordering accounts and higher average selling prices [14] - The company is focused on expanding the interventional dry eye market through investments in commercial infrastructure and provider engagement [11][12] Market Data and Key Metrics Changes - The interventional glaucoma market is expected to grow in the low to mid-single digits, while the interventional dry eye segment is projected to reach $5 million-$7 million in revenue for 2026 [20][26] - The company estimates that the current MIGS market is approximately 90% combo cataract and 10% standalone, with expectations for a shift towards standalone procedures [37] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A focus on interventional solutions is expected to create multiple durable growth drivers across glaucoma and dry eye categories [7] - The company is investing in targeted commercial resources to drive education and activation in the standalone glaucoma market [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven without raising additional equity capital, supported by a strong balance sheet [17] - The company is optimistic about the growth potential in both interventional glaucoma and interventional dry eye markets, with a focus on disciplined execution [22] - Management highlighted the importance of expanding market access and engaging with additional MACs and commercial payers throughout 2026 [12][22] Other Important Information - The company has established pricing for CPT code 0563T associated with the TearCare procedure, marking a significant milestone for the interventional dry eye business model [9] - The company ended Q4 with $92 million in cash and cash equivalents, down from $120.4 million at the end of 2024 [19] Q&A Session Summary Question: Guidance assumptions for interventional glaucoma and interventional dry eye - Management indicated a stable market for interventional glaucoma and expressed excitement about growth in both segments for 2026 [25][26] Question: Underlying market growth assumptions for interventional glaucoma - Management estimates low to mid-single digit market growth for interventional glaucoma [27] Question: Standalone glaucoma market evolution and obstacles - Management discussed the need for education and activation to convert understanding of interventions into actual cases, with a focus on procedural workflows [34][36] Question: Operating expenses and investment balance - Management emphasized a focus on commercial infrastructure investments while maintaining financial discipline [44][46] Question: Revenue opportunity in MACs for dry eye - Management highlighted a significant market opportunity in MACs with 10.4 million covered lives and a high prevalence of dry eye disease [47][49] Question: Peak sales potential for TearCare - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time [55][56] Question: Impact of new goniotomy codes on reimbursement - Management discussed potential changes in reimbursement for goniotomy and its implications for OMNI technology [69][70]